The company was unable to comply with requirements including having a minimum bid price of at least $1 per share and stockholder equity of at least $2.5 million.
The company aims through the effort to develop better understandings of Kaiser's ovarian cancer care pathways and where its tests might be able to offer improvements.
The funds will support development of a test for detection of multiple tick-borne diseases that Ceres plans to take through the US Food and Drug Administration.
Researchers have discovered four new proteins that contribute to disease progression in Huntington's Disease.
The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.
In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.
A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.
Researchers report in Nature this week that farming led to genomic adaptations in humans.
The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.